VANCOUVER, BC / ACCESSWIRE / January 12, 2017 / CVR Medical Corp. CVR Medical Corp. (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) is pleased to announce that its “Carotid Stenotic Scan” (CSS) device has received IRB approval for clinical trials, to be conducted through the NIH HF Network at Thomas Jefferson University Hospital under the supervision of Dr. David J. Whellan , MD, MHS, FACC, FAHA.
CVR Chief Operations Officer Tony Robinson states, “With IRB approval, we look forward to continuing our progress through this final phase of clinical trials. To be able to do so with Dr. Whellan at Thomas Jefferson is something CVR is very proud of.”
For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.